PDB Short entry for 1C2T HEADER TRANSFERASE 26-JUL-99 1C2T TITLE NEW INSIGHTS INTO INHIBITOR DESIGN FROM THE CRYSTAL STRUCTURE AND NMR TITLE 2 STUDIES OF E. COLI GAR TRANSFORMYLASE IN COMPLEX WITH BETA-GAR AND TITLE 3 10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID. COMPND MOL_ID: 1; COMPND 2 MOLECULE: GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; COMPND 3 CHAIN: A, B; COMPND 4 EC: 2.1.2.2; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: ESCHERICHIA COLI; SOURCE 3 ORGANISM_TAXID: 562; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 7 EXPRESSION_SYSTEM_PLASMID: PJS167 KEYWDS PURINE BIOSYNTHESIS, ANTI-CANCER AGENT, INHIBITOR COMPLEX, KEYWDS 2 TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR S.E.GREASLEY,M.M.YAMASHITA,H.CAI,S.J.BENKOVIC,D.L.BOGER,I.A.WILSON REVDAT 5 07-FEB-24 1C2T 1 REMARK REVDAT 4 04-OCT-17 1C2T 1 REMARK REVDAT 3 13-APR-11 1C2T 1 HETATM REVDAT 2 24-FEB-09 1C2T 1 VERSN REVDAT 1 05-JAN-00 1C2T 0 JRNL AUTH S.E.GREASLEY,M.M.YAMASHITA,H.CAI,S.J.BENKOVIC,D.L.BOGER, JRNL AUTH 2 I.A.WILSON JRNL TITL NEW INSIGHTS INTO INHIBITOR DESIGN FROM THE CRYSTAL JRNL TITL 2 STRUCTURE AND NMR STUDIES OF ESCHERICHIA COLI GAR JRNL TITL 3 TRANSFORMYLASE IN COMPLEX WITH BETA-GAR AND JRNL TITL 4 10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID. JRNL REF BIOCHEMISTRY V. 38 16783 1999 JRNL REFN ISSN 0006-2960 JRNL PMID 10606510 JRNL DOI 10.1021/BI991888A REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH Y.SU,M.M.YAMASHITA,S.E.GREASLEY,C.A.MULLEN,J.H.SHIM, REMARK 1 AUTH 2 P.A.JENNINGS,S.J.BENKOVIC,I.A.WILSON REMARK 1 TITL A PH-DEPENDENT STABILIZATION OF AN ACTIVE SITE LOOP OBSERVED REMARK 1 TITL 2 FROM LOW AND HIGH PH CRYSTAL STRUCTURES OF MUTANT MONOMERIC REMARK 1 TITL 3 GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE AT 1.8-1.9A REMARK 1 REF J.MOL.BIOL. V. 281 485 1998 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.1998.1931 REMARK 1 REFERENCE 2 REMARK 1 AUTH D.L.BOGER,N.-E.HAYNES,P.A.KITOS,J.WARREN,J.RAMCHARAN, REMARK 1 AUTH 2 A.E.MAROLEWSKI,S.J.BENKOVIC REMARK 1 TITL 10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID (10-FORMYL-TDAF): A REMARK 1 TITL 2 POTENT INHIBITOR OF GLYCINAMIDE RIBONUCLEOTIDE REMARK 1 TITL 3 TRANSFORMYLASE. REMARK 1 REF BIOORG.MED.CHEM. V. 5 1817 1997 REMARK 1 REFN ISSN 0968-0896 REMARK 1 DOI 10.1016/S0968-0896(97)00120-X REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 0.3 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 471792.210 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 78.9 REMARK 3 NUMBER OF REFLECTIONS : 18882 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.227 REMARK 3 FREE R VALUE : 0.265 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.900 REMARK 3 FREE R VALUE TEST SET COUNT : 917 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.009 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.10 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.23 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 54.70 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2077 REMARK 3 BIN R VALUE (WORKING SET) : 0.2810 REMARK 3 BIN FREE R VALUE : 0.3040 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 111 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.029 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3234 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 106 REMARK 3 SOLVENT ATOMS : 197 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 18.50 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 31.70 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -7.65000 REMARK 3 B22 (A**2) : 11.01000 REMARK 3 B33 (A**2) : -3.36000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 4.29000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.27 REMARK 3 ESD FROM SIGMAA (A) : 0.25 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.31 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.30 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.011 REMARK 3 BOND ANGLES (DEGREES) : 1.500 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 23.40 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.020 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.330 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.130 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.830 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.640 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PA REMARK 3 PARAMETER FILE 2 : WATER_REP.PARA REMARK 3 PARAMETER FILE 3 : GARA.PAR REMARK 3 PARAMETER FILE 4 : NEH9SH.PAR REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : GARA.TOP REMARK 3 TOPOLOGY FILE 3 : NEH9SH.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1C2T COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 28-JUL-99. REMARK 100 THE DEPOSITION ID IS D_1000009408. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-JUL-97 REMARK 200 TEMPERATURE (KELVIN) : 94 REMARK 200 PH : 7.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23742 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : 2.900 REMARK 200 R MERGE (I) : 0.08300 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 13.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.17 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.3 REMARK 200 DATA REDUNDANCY IN SHELL : 2.80 REMARK 200 R MERGE FOR SHELL (I) : 0.42100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.18 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.24 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 3350, IMIDAZOLE MALATE, CALCIUM REMARK 280 CHLORIDE, MPD, PH 7.2, VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 22.0K, TEMPERATURE 295K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 56.39500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 210 REMARK 465 ASP A 211 REMARK 465 GLU A 212 REMARK 465 ALA B 210 REMARK 465 ASP B 211 REMARK 465 GLU B 212 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 8 -21.50 -142.09 REMARK 500 ALA A 40 118.53 -35.91 REMARK 500 ALA A 79 61.48 38.52 REMARK 500 MET A 89 35.06 -85.57 REMARK 500 PRO A 109 38.59 -69.58 REMARK 500 THR A 120 -71.52 -46.76 REMARK 500 ASN A 127 11.15 -58.28 REMARK 500 LEU A 143 110.85 -34.32 REMARK 500 ASP A 144 19.45 50.88 REMARK 500 TYR A 208 125.78 -38.70 REMARK 500 SER B 8 -19.98 -143.29 REMARK 500 ALA B 40 119.85 -29.71 REMARK 500 PRO B 109 38.62 -68.02 REMARK 500 LEU B 143 105.27 -44.54 REMARK 500 TYR B 208 125.74 -38.02 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NHS B 220 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GAR B 221 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NHS A 222 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GAR A 223 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1C3E RELATED DB: PDB REMARK 900 C3E CONTAINS THE SAME PROTEIN COMPLEXED TO THE (10R)-10-FORMYL-TDAF REMARK 900 AND BETA GAR DBREF 1C2T A 1 212 UNP P08179 PUR3_ECOLI 1 212 DBREF 1C2T B 1 212 UNP P08179 PUR3_ECOLI 1 212 SEQRES 1 A 212 MET ASN ILE VAL VAL LEU ILE SER GLY ASN GLY SER ASN SEQRES 2 A 212 LEU GLN ALA ILE ILE ASP ALA CYS LYS THR ASN LYS ILE SEQRES 3 A 212 LYS GLY THR VAL ARG ALA VAL PHE SER ASN LYS ALA ASP SEQRES 4 A 212 ALA PHE GLY LEU GLU ARG ALA ARG GLN ALA GLY ILE ALA SEQRES 5 A 212 THR HIS THR LEU ILE ALA SER ALA PHE ASP SER ARG GLU SEQRES 6 A 212 ALA TYR ASP ARG GLU LEU ILE HIS GLU ILE ASP MET TYR SEQRES 7 A 212 ALA PRO ASP VAL VAL VAL LEU ALA GLY PHE MET ARG ILE SEQRES 8 A 212 LEU SER PRO ALA PHE VAL SER HIS TYR ALA GLY ARG LEU SEQRES 9 A 212 LEU ASN ILE HIS PRO SER LEU LEU PRO LYS TYR PRO GLY SEQRES 10 A 212 LEU HIS THR HIS ARG GLN ALA LEU GLU ASN GLY ASP GLU SEQRES 11 A 212 GLU HIS GLY THR SER VAL HIS PHE VAL THR ASP GLU LEU SEQRES 12 A 212 ASP GLY GLY PRO VAL ILE LEU GLN ALA LYS VAL PRO VAL SEQRES 13 A 212 PHE ALA GLY ASP SER GLU ASP ASP ILE THR ALA ARG VAL SEQRES 14 A 212 GLN THR GLN GLU HIS ALA ILE TYR PRO LEU VAL ILE SER SEQRES 15 A 212 TRP PHE ALA ASP GLY ARG LEU LYS MET HIS GLU ASN ALA SEQRES 16 A 212 ALA TRP LEU ASP GLY GLN ARG LEU PRO PRO GLN GLY TYR SEQRES 17 A 212 ALA ALA ASP GLU SEQRES 1 B 212 MET ASN ILE VAL VAL LEU ILE SER GLY ASN GLY SER ASN SEQRES 2 B 212 LEU GLN ALA ILE ILE ASP ALA CYS LYS THR ASN LYS ILE SEQRES 3 B 212 LYS GLY THR VAL ARG ALA VAL PHE SER ASN LYS ALA ASP SEQRES 4 B 212 ALA PHE GLY LEU GLU ARG ALA ARG GLN ALA GLY ILE ALA SEQRES 5 B 212 THR HIS THR LEU ILE ALA SER ALA PHE ASP SER ARG GLU SEQRES 6 B 212 ALA TYR ASP ARG GLU LEU ILE HIS GLU ILE ASP MET TYR SEQRES 7 B 212 ALA PRO ASP VAL VAL VAL LEU ALA GLY PHE MET ARG ILE SEQRES 8 B 212 LEU SER PRO ALA PHE VAL SER HIS TYR ALA GLY ARG LEU SEQRES 9 B 212 LEU ASN ILE HIS PRO SER LEU LEU PRO LYS TYR PRO GLY SEQRES 10 B 212 LEU HIS THR HIS ARG GLN ALA LEU GLU ASN GLY ASP GLU SEQRES 11 B 212 GLU HIS GLY THR SER VAL HIS PHE VAL THR ASP GLU LEU SEQRES 12 B 212 ASP GLY GLY PRO VAL ILE LEU GLN ALA LYS VAL PRO VAL SEQRES 13 B 212 PHE ALA GLY ASP SER GLU ASP ASP ILE THR ALA ARG VAL SEQRES 14 B 212 GLN THR GLN GLU HIS ALA ILE TYR PRO LEU VAL ILE SER SEQRES 15 B 212 TRP PHE ALA ASP GLY ARG LEU LYS MET HIS GLU ASN ALA SEQRES 16 B 212 ALA TRP LEU ASP GLY GLN ARG LEU PRO PRO GLN GLY TYR SEQRES 17 B 212 ALA ALA ASP GLU HET NHS A 222 35 HET GAR A 223 18 HET NHS B 220 35 HET GAR B 221 18 HETNAM NHS 10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID HETNAM GAR GLYCINAMIDE RIBONUCLEOTIDE FORMUL 3 NHS 2(C23 H22 N4 O8) FORMUL 4 GAR 2(C7 H13 N2 O8 P 2-) FORMUL 7 HOH *197(H2 O) HELIX 1 1 GLY A 11 THR A 23 1 13 HELIX 2 2 ALA A 40 ALA A 49 1 10 HELIX 3 3 ILE A 57 PHE A 61 5 5 HELIX 4 4 SER A 63 ASP A 76 1 14 HELIX 5 5 MET A 77 ALA A 79 5 3 HELIX 6 6 SER A 93 TYR A 100 1 8 HELIX 7 7 HIS A 119 ASN A 127 1 9 HELIX 8 8 SER A 161 ASP A 186 1 26 HELIX 9 9 GLY B 11 THR B 23 1 13 HELIX 10 10 ALA B 40 ALA B 49 1 10 HELIX 11 11 ILE B 57 PHE B 61 5 5 HELIX 12 12 SER B 63 ASP B 76 1 14 HELIX 13 13 MET B 77 ALA B 79 5 3 HELIX 14 14 SER B 93 TYR B 100 1 8 HELIX 15 15 HIS B 119 GLY B 128 1 10 HELIX 16 16 SER B 161 ASP B 186 1 26 SHEET 1 A 7 ALA A 52 THR A 55 0 SHEET 2 A 7 THR A 29 SER A 35 1 O ARG A 31 N ALA A 52 SHEET 3 A 7 ASN A 2 ILE A 7 1 N ILE A 3 O THR A 29 SHEET 4 A 7 VAL A 82 LEU A 85 1 O VAL A 82 N VAL A 4 SHEET 5 A 7 LEU A 104 HIS A 108 1 O LEU A 105 N LEU A 85 SHEET 6 A 7 GLU A 131 PHE A 138 -1 N SER A 135 O HIS A 108 SHEET 7 A 7 VAL A 148 PRO A 155 -1 N ILE A 149 O VAL A 136 SHEET 1 B 3 LEU A 189 HIS A 192 0 SHEET 2 B 3 ALA A 195 LEU A 198 -1 O ALA A 195 N HIS A 192 SHEET 3 B 3 GLN A 201 ARG A 202 -1 O GLN A 201 N LEU A 198 SHEET 1 C 7 ALA B 52 THR B 55 0 SHEET 2 C 7 THR B 29 SER B 35 1 O ARG B 31 N ALA B 52 SHEET 3 C 7 ASN B 2 ILE B 7 1 N ILE B 3 O THR B 29 SHEET 4 C 7 VAL B 82 LEU B 85 1 O VAL B 82 N VAL B 4 SHEET 5 C 7 LEU B 104 HIS B 108 1 N LEU B 105 O VAL B 83 SHEET 6 C 7 GLU B 131 PHE B 138 -1 N SER B 135 O HIS B 108 SHEET 7 C 7 VAL B 148 PRO B 155 -1 N ILE B 149 O VAL B 136 SHEET 1 D 3 LEU B 189 HIS B 192 0 SHEET 2 D 3 ALA B 195 LEU B 198 -1 O ALA B 195 N HIS B 192 SHEET 3 D 3 GLN B 201 ARG B 202 -1 O GLN B 201 N LEU B 198 CISPEP 1 LEU A 112 PRO A 113 0 5.38 CISPEP 2 LEU B 112 PRO B 113 0 0.26 SITE 1 AC1 17 GLU A 131 ARG B 64 PHE B 88 MET B 89 SITE 2 AC1 17 ARG B 90 ILE B 91 LEU B 92 VAL B 97 SITE 3 AC1 17 ASN B 106 HIS B 108 LEU B 118 VAL B 139 SITE 4 AC1 17 THR B 140 ASP B 141 GLU B 142 ASP B 144 SITE 5 AC1 17 GAR B 221 SITE 1 AC2 15 ASN B 10 GLY B 11 SER B 12 ASN B 13 SITE 2 AC2 15 GLY B 87 PHE B 88 MET B 89 ILE B 107 SITE 3 AC2 15 PRO B 109 GLU B 173 NHS B 220 HOH B 244 SITE 4 AC2 15 HOH B 246 HOH B 287 HOH B 289 SITE 1 AC3 18 ARG A 64 PHE A 88 MET A 89 ARG A 90 SITE 2 AC3 18 ILE A 91 LEU A 92 VAL A 97 ASN A 106 SITE 3 AC3 18 HIS A 108 LEU A 118 VAL A 139 THR A 140 SITE 4 AC3 18 ASP A 141 GLU A 142 LEU A 143 ASP A 144 SITE 5 AC3 18 GAR A 223 LYS B 153 SITE 1 AC4 12 GLY A 11 SER A 12 ASN A 13 GLY A 87 SITE 2 AC4 12 PHE A 88 MET A 89 ILE A 107 PRO A 109 SITE 3 AC4 12 GLU A 173 NHS A 222 HOH A 227 HOH A 234 CRYST1 40.250 112.790 46.960 90.00 101.50 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.024845 0.000000 0.005055 0.00000 SCALE2 0.000000 0.008866 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021731 0.00000